FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Wall St set for lower open as hot inflation data fuels rate-hike bets
- Oil prices surge as Iran deploys new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Takeda's TAK-881 meets primary endpoint in Phase 2/3 PID trial
Tweet Send to a Friend
Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) announced results from its pivotal Phase 2/3 IgGNITE clinical trial evaluating investigational TAK-881 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
